Loading…
IN8bio, Inc. is projected to decline to $1.15 by 2027, a -4% move from its current price of $1.20. INAB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $1.17 | $1.20 | $1.23 | -0.02% |
| Jul 27 | $1.15 | $1.20 | $1.25 | -0.03% |
| Jul 28 | $1.14 | $1.20 | $1.26 | -0.05% |
| Jul 29 | $1.13 | $1.20 | $1.27 | -0.07% |
| Jul 30 | $1.13 | $1.20 | $1.28 | -0.09% |
| Jul 31 | $1.12 | $1.20 | $1.28 | -0.10% |
| Aug 1 | $1.11 | $1.20 | $1.29 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.11 | $1.20 | $1.29 | -0.12% |
| Week 2 | $1.08 | $1.20 | $1.33 | -0.24% |
| Week 3 | $1.05 | $1.20 | $1.36 | -0.36% |
| Week 4 | $1.03 | $1.19 | $1.39 | -0.48% |
| Week 5 | $1.01 | $1.19 | $1.41 | -0.60% |
| Week 6 | $0.9914 | $1.19 | $1.43 | -0.72% |
| Week 7 | $0.9757 | $1.19 | $1.45 | -0.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases.
Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
IN8bio, Inc. trades under the ticker INAB and has a current price of $1.26, with a market capitalization of $12.08M and a market rank of 4751.
The price outlook derived from the year by year forecast shows a path from near term stability toward longer term upside. The forecasted 2026 average price is $1.26, rising to $1.22 in 2027, $1.54 in 2028, $1.64 in 2030, $2.16 in 2040, and $4.29 in 2050.
The forecast also provides max values such as $2.44 for 2030 and $8.26 for 2050, with long horizon ROIs of 30.4% in 2030, 71.5% in 2040, and 240.2% in 2050.
A major floor 16.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
The nearest ceiling, 23.3% above — a clean break opens room to run.
A major ceiling 71.7% above — clearing it would confirm fresh momentum.
Key INAB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INAB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.25 | Sell | $1.25 | Sell |
| MA 10 | $1.31 | Sell | $1.29 | Sell |
| MA 20 | $1.36 | Sell | $1.35 | Sell |
| MA 50 | $1.47 | Sell | $1.43 | Sell |
| MA 100 | $1.53 | Sell | $1.55 | Sell |
| MA 200 | $1.74 | Sell | $2.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.85 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -192.88 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -14.39 | Sell |
| Bollinger %B (20,2) | -0.08 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.46 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 24.49 | Buy |
| Momentum (10) | -0.21 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.19 | Buy |
| ADX (14) | 18.11 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is BEARISH.
RSI14 is 40, indicating some momentum weakness, while the SMA50 stands at $1.49 and the SMA200 at $1.75.
Support is at $1.26 and resistance at $1.48, with a 30-day price range from $1.03 to $1.54.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.19 | $1.20 | $1.49 | 0% | Neutral | |
| $0.9144 | $1.15 | $1.53 | -4% | Neutral | |
| $1.10 | $1.42 | $1.97 | +19% | Neutral | |
| $1.13 | $1.50 | $2.14 | +25% | Bullish | |
| $1.13 | $1.53 | $2.24 | +28% | Bullish | |
| $1.13 | $1.57 | $2.34 | +31% | Bullish | |
| $1.02 | $1.44 | $2.20 | +20% | Neutral | |
| $1.06 | $1.53 | $2.37 | +27% | Bullish | |
| $1.07 | $1.55 | $2.45 | +29% | Bullish | |
| $1.09 | $1.62 | $2.59 | +35% | Bullish | |
| $1.27 | $2.02 | $3.46 | +69% | Bullish | |
| $2.19 | $3.92 | $7.36 | +227% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.19 | $1.20 | $1.42 | +0.00% |
| August 2026 | $1.01 | $1.19 | $1.44 | -0.49% |
| September 2026 | $0.9956 | $1.18 | $1.44 | -1.07% |
| October 2026 | $1.02 | $1.22 | $1.51 | +3.50% |
| November 2026 | $1.03 | $1.23 | $1.54 | +0.87% |
| December 2026 | $0.9831 | $1.19 | $1.49 | -3.75% |
Click any year to see its month-by-month INAB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, INAB is projected to trade between $1.19 and $1.49, averaging $1.20 — a potential gain of 0% from today's $1.20. A consolidation phase looks the most probable path here.
IN8bio, Inc.'s 2027 outlook centres on $1.15, within a $0.9144 to $1.53 range. That is -4% versus the projected 2026 average. That marks a -4% change versus current levels. Price action looks broadly range-bound.
By 2028, INAB could reach as high as $1.97, with a base case around $1.42 and support toward $1.10 — roughly +19% from $1.20. A consolidation phase looks the most probable path here.
Expect INAB to range from $1.13 to $2.14 through 2029. The $1.50 average target implies a +25% move from current prices. That is up +5% on the projected 2028 average. Momentum favours further upside here.
The INAB price prediction for 2030 points to an average of $1.53 (low $1.13, high $2.24) — a potential gain of +28% on today's $1.20. Buyers look set to stay in control over this stretch.
In 2031, INAB is projected to trade between $1.13 and $2.34, averaging $1.57 — a potential gain of +31% from today's $1.20. That is up +2% on the projected 2030 average. Momentum favours further upside here.
IN8bio, Inc.'s 2032 outlook centres on $1.44, within a $1.02 to $2.20 range. That is -8% versus the projected 2031 average. That marks a +20% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, INAB could reach as high as $2.37, with a base case around $1.53 and support toward $1.06 — roughly +27% from $1.20. Momentum favours further upside here.
Expect INAB to range from $1.07 to $2.45 through 2034. The $1.55 average target implies a +29% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The INAB price prediction for 2035 points to an average of $1.62 (low $1.09, high $2.59) — a potential gain of +35% on today's $1.20. Momentum favours further upside here.
In 2040, INAB is projected to trade between $1.27 and $3.46, averaging $2.02 — a potential gain of +69% from today's $1.20. That is up +25% on the projected 2035 average. Buyers look set to stay in control over this stretch.
IN8bio, Inc.'s 2050 outlook centres on $3.92, within a $2.19 to $7.36 range. That is up +94% on the projected 2040 average. That marks a +227% change versus current levels. Momentum favours further upside here.
Investing $1,000 in INAB today (≈ 833.333333 INAB) could be worth
$3,270.77
+$2,270.77 (+227%) by 2050 · US Dollar
Based on the average projected INAB price of $3.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INABwould be worth at today's price.
$1,000 invested in INAB on Jul 23, 2025 (≈ 406.504059 INAB) would be worth
$487.8
-$512.2 (-51.2%) today · 0.49× · US Dollar
Based on a INAB entry price of $2.46 vs. today's $1.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.38 | $869.57 | -13.0% |
| 1 month ago | $1.46 | $821.92 | -17.8% |
| 3 months ago | $1.5 | $800 | -20.0% |
| 6 months ago | $2.4 | $500 | -50.0% |
| 1 year ago | $2.46 | $487.8 | -51.2% |
| All time (5.0y) ago | $300 | $4 | -99.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INAB forecast.
Our base-case forecast reaches $2.40 around 2050.
Implied market cap at $2.40: $23.02M
The multi-year forecast shows a mix of near-term neutral years and longer-term bullish years.
In 2026 the min price is $1.26, the avg is $1.26, the max is $1.57, with ROI of 0% and sentiment NEUTRAL; in 2027 the min is $0.9646, the avg is $1.22, the max is $1.65, ROI -2.9%, sentiment NEUTRAL.
From 2028 onward, the forecast shows higher average prices with bullish sentiment, with 2028 avg $1.54, 2029 avg $1.61, 2030 avg $1.64, 2031 avg $1.68, 2032 avg $1.53, 2033 avg $1.63, 2034 avg $1.66 and 2035 avg $1.75, all labeled BULLISH and featuring positive ROIs (22% in 2028, 27.6% in 2029, 30.4% in 2030, 33% in 2031, 21.2% in 2032, 29.6% in 2033, 32% in 2034, 38.7% in 2035).
By 2040 the avg price is $2.16 with a max of $3.78 and ROI of 71.5%, and by 2050 the avg price is $4.29 with a max of $8.26 and ROI of 240.2%, both with bullish sentiment.
Overall, the long horizon signals upside potential, but near-term uncertainty remains given the neutral to modest gains in the earlier years and the volatility implied by the forecast.
Tap a question to reveal the answer.
The forecast shows an average price of $1.64 in 2030, with a min of $1.19 and a max of $2.44, and a projected ROI of 30.4%. The sentiment is BULLISH.
Near term is shown as NEUTRAL to BEARISH in the 2026 and 2027 periods, while longer term shows BULLISH sentiment from 2028 onward with increasing upside, including an average price of $4.29 and ROI of 240.2% by 2050. These are estimates, not guarantees.
The 2050 forecast max is $8.26, which implies a path above $5 by 2050 according to the forecast. In earlier years the max prices are lower (2030 max $2.44, 2040 max $3.78).
Current price is $1.26 and market cap is $12.08M.
Bearish sentiment with RSI 40; SMA50 at $1.49 and SMA200 at $1.75. Support is at $1.26 and resistance at $1.48, with a 30-day range from $1.03 to $1.54.
IN8bio, Inc. Community Discussion
0Share your IN8bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.